167 studies found for:    "Haemophilus influenzae"
Show Display Options
Rank Status Study
21 Completed
Has Results
Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™
Conditions: Diphtheria;   Tetanus;   Pertussis;   Hepatitis B;   Poliomyelitis;   Haemophilus Influenzae Type B Infection
Interventions: Biological: DTaP-IPV-Hep B-PRP~T vaccine (Batch 1);   Biological: DTaP-IPV-Hep B-PRP~T vaccine (Batch 2);   Biological: DTaP-IPV-Hep B-PRP~T vaccine (Batch 3);   Biological: Infanrix Hexa™
22 Active, not recruiting Database Surveillance Safety Study of PENTACEL® Vaccine
Conditions: Diphtheria;   Tetanus;   Pertussis;   Haemophilus Influenzae
Interventions: Biological: DTaP-IPV/Hib;   Biological: Other DTap Vaccines
23 Recruiting Exploratory Clinical Study of MT-2301
Condition: Haemophilus Influenza Type b
Interventions: Biological: Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-Low + DPT-IPV;   Biological: Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-High + DPT-IPV;   Biological: Haemophilus influenza type b conjugate vaccine + DPT-IPV
24 Completed Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants.
Conditions: Diphtheria;   Tetanus;   Pertussis;   Poliomyelitis;   Haemophilus Influenzae Type B
Interventions: Biological: PENTAXIM™: DTacP IPV//PRP~T combined vaccine;   Biological: TETRAXIM™: DTacP IPV combined vaccine and ActHIB™: PRP tetanus conjugate vaccine
25 Completed Immunogenicity and Safety of Pentaxim as 3 Doses Primary Vaccination Followed by a Booster Dose at 18 Months
Conditions: Diphtheria;   Tetanus;   Haemophilus Influenzae Type b;   Pertussis;   Poliomyelitis
Interventions: Biological: Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib;   Biological: Diphtheria, Tetanus, & Acellular Pertussis Combined, Absorbed
26 Completed Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended Vaccine
Conditions: Diphtheria;   Tetanus;   Whooping Cough;   Polio;   Haemophilus Influenzae Type b
Interventions: Biological: DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine);   Biological: Pentacel: DTaP-IPV/Hib
27 Completed Phase IV Interchangeability Study of a Liquid Pentavalent Combination Vaccine
Conditions: Diphtheria;   Tetanus;   Pertussis;   Hepatitis B;   Haemophilus Influenzae Type B
Interventions: Biological: Shan 5;   Biological: Easy Five
28 Completed
Has Results
Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants
Condition: Haemophilus Influenzae Type b
Interventions: Biological: GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108);   Biological: ActHIB™;   Biological: Pentacel™;   Biological: Pediarix™;   Biological: Prevnar 13™;   Biological: Rotarix™;   Biological: Engerix™-B;   Biological: Infanrix™
29 Unknown  Seroimmunity 2007 and Sub Study of the Swedish Population Regarding Vaccine Preventable Disease
Conditions: Diphtheria;   Tetanus;   Pertussis;   Polio;   Haemophilus Influenzae Type B;   Measles;   Mumps;   Rubella;   Hepatitis B
Intervention:
30 Completed
Has Results
Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean Infants
Conditions: Diphtheria;   Tetanus;   Pertussis;   Haemophilus Influenzae Type b;   Poliomyelitis
Interventions: Biological: DTaP-IPV-HB-PRP~T;   Biological: DTaP-IPV//PRP~T combined vaccine & Recombinant hep B vaccine
31 Completed
Has Results
Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months.
Conditions: Diphtheria;   Tetanus;   Pertussis;   Haemophilus Influenzae Type b;   Hepatitis B
Interventions: Biological: DTaP-IPV-HB-PRP~T;   Biological: Tritanrix-HepB/Hib
32 Completed Safety and Immunogenicity Study of a Liquid Pentavalent Combination Vaccine
Conditions: Diphtheria;   Tetanus;   Pertussis;   Hepatitis B;   Haemophilus Influenzae Type B
Intervention: Biological: Shan5
33 Completed
Has Results
Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™
Conditions: Diphtheria;   Tetanus;   Pertussis;   Hepatitis B;   Haemophilus Influenzae Type b
Interventions: Biological: DTaP-HB-PRP~T vaccine;   Biological: Tritanrix-HepB/Hib™;   Biological: Oral Polio Vaccine
34 Completed
Has Results
Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Infanrix®Hexa in Healthy Peruvian Infants
Conditions: Diphtheria;   Tetanus;   Pertussis;   Haemophilus Influenzae Type b;   Hepatitis B
Interventions: Biological: DTaP IPV HB PRP~T vaccine;   Biological: DTaP-HB-IPV and Haemophilus influenzae type b
35 Unknown  Safety, Long Term Immunogenicity and Lot Consistency Study of Liquid Pentavalent Combination Vaccine
Conditions: Diphtheria;   Tetanus;   Pertussis;   Hepatitis B;   Haemophilus Influenzae Type B
Intervention: Biological: Shan 5
36 Completed Immunogenicity, Safety & Reactogenicity of GSK Vaccine Tritanrix™-HepB/Hib2.5 Compared to GSK Vaccine Tritanrix™-HepB/Hiberix™
Condition: Haemophilus Influenzae Type b
Interventions: Biological: Tritanrix™-HepB low thio /;   Biological: Hib 2.5;   Biological: Tritanrix™-HepB;   Biological: Hiberix™;   Biological: Unconjugated Hib vaccine (plain PRP)
37 Completed Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine
Conditions: Haemophilus Influenzae Type b;   Neisseria Meningitidis
Interventions: Biological: Menitorix;   Biological: Infanrix IPV
38 Completed
Has Results
Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines
Conditions: Neisseria Meningitidis;   Haemophilus Influenzae Type b
Interventions: Biological: MenitorixTM;   Biological: Pneumococcal conjugate vaccine GSK1024850A;   Biological: PrevenarTM;   Biological: MeningitecTM;   Biological: NeisVac-CTM;   Biological: InfanrixTM hexa;   Biological: InfanrixTM penta;   Biological: InfanrixTM IPV/Hib;   Biological: InfanrixTM IPV
39 Completed Safety & Immunogenicity of Pneumococcal Vaccine 2189242A in Children Aged 12-23 Months at the Time of First Vaccination
Conditions: Pneumococcal Disease;   Haemophilus Influenzae Infections
Interventions: Biological: Pneumococcal vaccine GSK2189242A (formulation 1);   Biological: Pneumococcal vaccine GSK2189242A (formulation 2);   Biological: Pneumococcal vaccine GSK2189242A combined with pneumococcal vaccine GSK1024850A (formulation 3);   Biological: Pneumococcal vaccine GSK2189242A combined with pneumococcal vaccine GSK1024850A (formulation 4);   Biological: Pneumococcal vaccine GSK1024850A
40 Completed Impact on Carriage, Acute Otitis Media, Immuno & Safety of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A
Conditions: Streptococcus Pneumoniae;   Pneumococcal Disease;   Haemophilus Influenzae Infections
Interventions: Biological: Pneumococcal conjugate vaccine GSK1024850A;   Biological: GSK Biologicals' Engerix TM vaccine (Hepatitis B vaccine);   Biological: GSK Biologicals' Havrix TM vaccine (Hepatitis A vaccine)

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years